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Abstract 
Background: The Affordable Medicine Facility‑malaria (AMFm) was an innovative global financing mechanism for 
the provision of quality‑assured artemisinin‑based combination therapy (ACT) across both the private and public 
health sectors in eight countries in sub‑Saharan Africa. This study evaluated the effectiveness of AMFm subsidies in 
increasing access to ACT in Ghana and documented malaria management practices at the household and commu‑
nity levels during the implementation of the AMFm.
Methods: This study, conducted in four regions in Ghana between January, 2011 to December, 2012, employed 
cross‑sectional mixed‑methods design that included qualitative and quantitative elements, specifically household 
surveys, focus group discussions (FGD) and in‑depth interviews.
Results: The study indicated high ACT availability, adequate provider knowledge and reasonably low quality‑assured 
ACT use in the study areas, all of which are a reflection of a high market share of ACT in these hard‑to‑reach areas of 
the country. Adequate recognition of childhood malaria symptoms by licensed chemical seller (LCS) attendants was 
observed. A preference by caregivers for LCS over health facilities for seeking treatment solutions to childhood malaria 
was found.
Conclusions: Artemisinin‑based combination therapy with the AMFm logo was accessible and affordable for most 
people seeking treatment from health facilities and LCS shops in rural areas. Caregivers and LCS were seen to play key 
roles in the health of the community especially with children under 5 years of age.
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Background
The Affordable Medicine Facility-malaria (AMFm) was 
an innovative global financing mechanism for the provi-
sion of quality assured artemisinin-based combination 
therapy (ACT) across both the private and public health 
sectors in eight countries in sub-Saharan Africa. The 
mechanism provided a subsidy at the manufacturer level 
together with a set of supporting interventions. A green 
leaf logo is affixed to all ACT drugs supported by the 
AMFm programme for easy identification and quality 
assurance. The objectives of the AMFm were to expand 
access to quality-assured ACT (QAACT) and to delay 
resistance to artemisinin monotherapies [1].
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Ghana was one of the eight implementing countries of 
the AMFm initiative [2]. The others were Kenya, Cambo-
dia, Madagascar, Niger, Nigeria, Tanzania and Uganda. 
Implementation began in August, 2010 when the first 
batch of QAACT was brought into the country. A total 
of 52.7 million treatment doses of the subsidized ACT 
was imported into Ghana from August, 2010 to Decem-
ber, 2012. Majority (48.1 million) was brought in by the 
private sector representing 90 % of total orders [3]. The 
private-for-profit health care sector in Ghana includes 
licensed chemical sellers (LCS) who are also the first 
point of care for febrile illnesses, especially in remote and 
hard-to- reach areas. There are more than 10,000 LCS 
shops in the Ghana [4].
As in most countries in the sub-region, the general 
population of Ghana is at risk for malaria but the most 
vulnerable include children under 5 years old and preg-
nant women [5], hence the role of caregivers in providing 
prompt and effective care for children under-five is criti-
cal. This role is endorsed by the National Malaria Con-
trol Programme (NMCP), which is the main government 
agency responsible for prevention and control of malaria 
in Ghana. The main prevention and control measures 
used in sub-Saharan Africa are: promotion of use of 
insecticide-treated nets (ITNs); indoor residual spraying 
(IRS); intermittent presumptive treatment for pregnant 
women with sulfadoxine-pyrimethamine (SP) and early 
detection and prompt treatment of malaria [5–8]. There 
is considerable evidence of utilization of these interven-
tions [9] whose implementation has led to improvement 
in related health indicators [10]).
The Global Fund conducted an independent evalua-
tion of the AMFm pilot in all eight countries from 2009 
to 2011 and showed that the concept was successful [11]. 
However, countries continued to implement the AMFm 
until December, 2012. This study, therefore, sought to 
evaluate the AMFm programme in Ghana between 2011 
and 2012. The main objectives of the study were to: (i) 
evaluate the effectiveness of AMFm subsidies in increas-
ing access to ACT in Ghana and, (ii) document malaria 
management practices at the household and community 
levels during the implementation of the AMFm. As an 
extension to previous work done [12, 13], this study also 
focuses on the role of key stakeholders such as caregivers, 




This study employed cross-sectional mixed methods 
that included qualitative and quantitative elements. 
Household surveys, focus group discussions (FGD) and 
in-depth interviews were carried out between January, 
2011 to December, 2012.
Study setting
This study was conducted in five sites from four of the 
ten regions of Ghana: they are the Asante-Akim North 
and South Districts in the Ashanti Region, Shama Dis-
trict in the Western Region, Kpone-Katamanso District 
in the Greater Accra Region, and West Gonja District 
in the Northern Region. These study sites are located in 
the three ecological zones (Forest, Coastal, and Savan-
nah) in Ghana. Asante-Akim North and South Districts 
are located in the Forest Zone and occupy 1462  km2 
and 1217.7 km2 of land, respectively. The Shama district 
occupies an area of 384 km2 and it is located within the 
Coastal-Forest zone while the Kpone-Katamanso Dis-
trict, which occupies an area of 215.4  km2, is located 
in the Coastal-Savannah zone. The West Gonja Dis-
trict occupies an area of 17,317  km2 and is located in 
the Savannah zone. The main economic activities of the 
selected districts are subsistence farming, animal hus-
bandry and fishing. However, a considerable number 
of the inhabitants in all the study sites engage in petty 
trading. Aside from the differences in ecology the pop-




These included caregivers of children under-five, LCS 
and health care providers. A total of 285 caregivers were 
enrolled (Asante-Akim North, N  =  57; Asante-Akim 
South, N  =  54; Shama, N  =  60; Kpone-Katamanso, 
N = 54; and West Gonja, N = 60). All LCS in the study 
sites were enrolled, N  =  149 (Asante-Akim North, 
N =  36; Asante-Akim South, N =  34; Shama, N =  36; 
Kpone-Katamanso, N = 34; West Gonja, N = 9). Twenty-
one health care providers also participated.
Study procedure
Appropriate sensitization was done through commu-
nity durbars and meetings to explain the purpose of 
the study and answer questions at the suitable literacy 
level. Informed consent was obtained from each study 
participant.
Data collection for the study comprised household sur-
veys, FGD and in-depth interviews. Structured question-
naire were administered to ascertain respondents’ views 
on relevant themes. For caregivers, the questionnaire 
sought to ascertain knowledge on malaria, first point 
of seeking care for malaria cases in children, attitude 
towards malaria prevention, control and treatment. The 
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questionnaire for LCS sought to determine their role in 
promoting treatment compliance to ACT, correct drug 
administration, and their perceptions on efficacy and 
availability of ACT in the treatment of malaria in children 
under 5  years of age. Health care providers were inter-
viewed using an interview guide to find out their views 
on the circumstances for prescribing ACT and other 
anti-malarial and in addition their prescribing behaviour 
was observed. The guide also sought information on the 
perception of health care providers on the availability, 
quality and reach of the AMFm ACT. The health care 
providers were community health nurses, disease control 
officers, physicians and pharmacists.
Twenty FGDs were held across the five districts. Each 
FGD comprised 8–12 individuals per session. For each 
site there were four FGDs; two male and two female 
groups of caregivers. The caregivers included mothers, 
fathers, grandparents, and other extended family mem-
bers. The male and female groups were separated to allow 
freedom of expression as socio-cultural practices limits 
females’ expression and participation in the presence of 
their male counterparts. The female caregivers were ran-
domly selected at the outpatient departments (OPD) of 
health facilities and women’s groups in the communities. 
On the other hand, male participants were recruited at 
the household level; this is because they are not the ones 
who usually send their under-5  year old children to the 
health facility for treatment.
Semi-structured and in-depth interviews were con-
ducted for the LCS to determine their role in the AMFm 
activities in Ghana, including awareness of AMFm, pref-
erence or otherwise for specific anti-malaria medicines 
including AMFm ACT, ease of access and cost of ACT, 
perceptions on efficacy and quality, and perceptions 
on preference of community members for anti-malaria 
medication.
The views of policy makers were sought on the AMFm 
supply chain management, and the quality and avail-
ability of health care at the rural levels in Ghana. These 
officials were purposively sampled and were given self-
administered questionnaire. In-depth interviews were 
held with five health policy officials at the national level 
on their role and contribution to malaria diagnosis and 
treatment.
Ethical consideration
Ethical approval for the study was obtained from the 
Ghana Health Service Ethical Review Committee 
(GHS-ERC:10/7/11), the University of Ghana School 
of Medicine and Dentistry Ethical and Protocol Review 
Committee (MS-Et/M.11-P.5.3/2010-11) and the Johns 
Hopkins Bloomberg School of Public Health Insti-
tutional Review Board, Maryland, USA (IRB 3482). 
Written informed consent was obtained from all partici-
pants. During the process, prospective participants were 
assured that the information they provide will be treated 
with strict confidentiality.
Statistical analysis
Data were doubly entered and afterwards validated 
to ensure consistency. Univariate analysis produced 
descriptive statistics presented as proportions. Bivariate 
analysis was done to determine associations between the 
outcome variable (access to AMFm ACT measured by 
affordability, availability and market share) and selected 
explanatory variables. All analyses were performed using 
SPSS Version 15.0 (SPSS Inc. Chicago). P value less than 
0.05 was considered statistically significant.
Results
Table 1 presents the characteristics of the different par-
ticipants (caregivers, LCS attendants, and healthcare 
providers) of the study. The majority (77.1 %) of the car-
egivers were mothers of children under 5  years old. Of 
the 105 caregivers, 101 responded to the question on lit-
eracy out of these 54 % could read and write in English. 
About 70 % of the caregivers were employed in the infor-
mal sector and they included hairdressers, fishmongers, 
seamstress, traders and farmers. LCS attendants were 
mostly males, and tended to be married or cohabiting. 
Over 90 % of the LCS attendants had completed at least 
Senior High School education. In addition, most (81 %) 
had received training on malaria symptom recognition 
and treatment protocols from the Pharmacy Council and 
the NMCP.
At the time of this survey, ACT was the most fre-
quently purchased anti-malarial at the LCS. The most 
popular ACT at the time was artemether-lumefantrine. 
Of note, however, were the purchase of monotherapies 
(Amodiaquine) and some other non-ACT anti-malarial. 
The frequency of anti-malarial medicines by study site is 
depicted in Fig. 1.
Across the four regions there was a trend towards fewer 
LCSs located within 100 metres of a health facility. Over-
all, there were fewer LCSs that had in stock the ACT with 
the AMFm Green Leaf logo. However, among those who 
stocked the AMFm ACT, there were more LCSs selling 
at 1.50 Ghana cedis or less, which was the recommended 
selling price. Thus, ACT was generally affordable, but not 
necessarily accessible. This did not significantly differ by 
study site (P > 0.05; Table 2).
Table 3 summarizes the malaria management practices 
of caregivers of children under 5  years. Caregivers pur-
chase of anti-malarial for children under 5  years were 
motivated by various signs including hot body (38  %), 
vomiting (14 %), and loss of appetite (17 %). About 2 % 
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of the caregivers sought anti-malarial from LCSs for their 
convulsing children. The drugs bought were mostly tab-
lets (44 %), syrups (26 %), and dispersible forms (25 %). 
Generally, caregivers intended to administer drugs 
bought orally.
Malaria management practices by caregivers, LCS 
and health care providers
Licensed chemical sellers
The LCS engaged the customers in an interaction by ask-
ing questions about whom the drug was being bought for. 












  Type of caregiver N = 20 N = 19 N = 20 N = 21 N = 25 N = 105
   Mother of young child 11 (55) 16 (84.2) 19 (95) 14 (66.7) 21 (84) 81 (77.1)
   Father of young child 5 (25) 2 (10.5) 0 4 (19) 4 (16) 15 (14.3)
   Other 4 (20) 1 (5.3) 1 (5) 3 (14.3) 0 9 (8.6)
  Literacy of caregivers N = 20 N = 18 N = 19 N = 20 N = 24 N = 101
   Cannot read and write English 4 (20) 10 (55.6) 13 (68.4) 5 (25) 15 (62.5) 47 (46.6)
   Can read and write English,  
but with difficulty
6 (30) 5 (27.8) 2 (10.6) 9 (45) 5 (20.8) 27 (26.7)
   Can read and write English easily 10 (50) 3 (16.7) 4 (21) 6 (30) 4 (16.7) 27 (26.7)
  Occupation of Caregivers N = 20 N = 19 N = 20 N = 21 N = 25 N = 105
   Unemployed 1 (5) 1 (5.30 1 (5) 0 0 3 (2.9)
   Formal sector 5 (25) 4 (21) 0 2 (9.5) 3 (12.0) 14 (13.3)
   Informal sector 14 (70) 14 (74) 19 (95) 19 (90.5) 22 (88.0) 88 (83.8)
 LCS attendants
  Gender N = 19 N = 20 N = 20 N = 20 N = 10 N = 89
   Male 15 (78.9) 16 (80.0) 13 (65.0) 12 (60.0) 9 (90.0) 65 (73.1)
   Female 4 (21.1) 4 (20.0) 7 (35.0) 8 (40.0) 1 (10.0) 24 (26.9)
   Marital status N = 19 N = 20 N = 20 N = 20 N = 10 N = 89
   Married/cohabiting 9 (47.4) 14 (70) 14 (70.0) 8 (40.0) 7 (70.0) 52 (58.4)
   Divorced/separated 2 (10.5) 4 (20) 1 (5.0) 0 0 7 (7.9)
   Never married/never co‑habited 8 (42.1) 2 (10) 5 (25.0) 12(60.0) 3 (30.0) 30 (33.7)
  Education N = 19 N = 20 N = 20 N = 20 N = 10 N = 89
   Primary education 4 (21.1) 1 (5.0) 1 (5.0) 1 (5.0) 1 (10.0) 8 (9.0)
   Secondary/SHS 11 (57.8) 13 (65.0) 12 (60.0) 11 (55.0) 8 (80.0) 55 (61.8)
   Tertiary 4 (21.1) 6 (30.0) 7 (35.0) 8 (40.0) 1 (10.0) 26 (29.2)
  Receipt of LCS training N = 19 N = 20 N = 20 N = 20 N = 10 N = 89
   Yes 8 (42.1) 20 (100) 20 (100) 16 (80) 10 (100) 74 (83.1)
   No 11 (57.9) 0 0 4 (20) 0 15 (16.9)
 Health care providers
   Nurse prescriber – 11 (52.4)
   Physician assistant 7 (33.3)
   Pharmacy technician 2 (9.5)
   Laboratory technologist 1 (4.8)
  Gender
   Male – 7 (33.3)
   Female 14 (66.7)
  Length of practice
   Up to 5 years – 10 (47.6)
   6–10 years 2 (9.5)
   Above 10 years 9 (42.9)
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Various questions were asked including, the body tem-
perature of the child, age of the person going to take the 
drug and signs and symptoms the person is presenting 
and whether the patient has diarrhoea.
Below are some of the questions as reported by their 
clients:
  • “He asked me of the signs of the illness and the number 
of days the child had been sick?”
  • “He asked me whether I had given the child any drug 
before coming?”
  • “Is the child able to breastfeed? Does she vomit?”
  • “The shopkeeper asked me if the child had really lost 
appetite, very hot and was not playing?”
After selling the drug to the customers most of the LCS 
gave information about the drug purchased. Some of the 
information given include;
  • “Give it two times in a day for three days. Give 10mls 
at a time.”
  • “Give morning and evening. Give after meals with 
plenty water.”
  • “Give the child food before administering the drug. 
Give half white and half yellow at a time for two 
times in a day for three days.”
  • “Give two times in a day for two days and come for 
the third drug some other time. Give half yellow, half 
white at a time.”
  • “He said when the child takes the drug and feels weak 
I should not worry is the nature of the drug and I 
should not give more than the right dosage.”
  • “Should be dissolved in water for twice daily before 
giving to the child.”
  • “The drug should be kept in dry place and remain 
in the box (package). The tablet should be dis-
solved in small amount of water before giving to 
the child.”
  • “The shop keeper told me that, this drug is effective 
in treating malaria and is less expensive and has the 
green leaf logo on it.”
Caregivers
Caregivers in this study prefer seeking care at LCS shops 
as against the health facilities. Caregivers indicated rea-
sons for their choices bothering on the timing of the ill-
ness, proximity to LCS and unbearable duration of time 
spent at the health centre.
  • “I don’t have time to go and queue at the hospital.”
  • “Because it was closer to my house, compared to the 
health centre.”
Fig. 1 Distribution of anti‑malarial drugs clients purchased at LCS by study site. The figure presents the distribution of anti‑malarial drugs that 
caregivers of children under 5 years had purchased from LCS by study site. Exit interviews were conducted with caregivers, who had purchased anti‑
malarial drugs for their children under 5 years. The range of drugs included AS/AL, AL, DP, and Amodiaquine as detailed in the legend below
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  • “It was in the night, when I send him to hospital I 
don’t think I will meet somebody there, so I took him 
to the drug store.”
  • “It was a Saturday and I didn’t know whether the hos-
pital was working or not and I didn’t want to keep her 
until Monday so I decided to send her to the drug 
store.”
  • “The child’s body was hot and the drug shop is close 
to my house so I decided to go and complain to the 
LCS.”
Cost and affordability of AMFm drugs
Caregivers were asked why they decided to go the drug 
shop and various responses were elicited. Some of the 
reasons given by the caregivers that related to finances 
and health insurance were;
  • “I didn’t have enough money at home as at the time 
the symptoms started so I decided to get first aid at 
the drug shop”.
  • “Because I don’t have Health Insurance”.
  • “Child’s NHIS card was in father’s room which was 
locked.”
  • “I do not have insurance so I went to the drug shop 
so that the cost will be lesser than the hospital”.
  • “I do not have money to take my child to the hospital 
so I decided to buy drugs from the drug store.”
Other reasons given by the caregivers which related 
to experience with that particular drug, for first aid and 
trust for the LCS prescription amongst others were;
Table 2 Access to, and affordability of AMFm ACTs as measured by proximity, price, and availability in the study sites
† There were no data recorded on Affordability for Shama district





Shama Kpone Katamanso 
District
West Gonja
Total number of LCS per 
district
N = 36 (%) N = 34 (%) N = 36 (%) N = 34 (%) N = 9 (%) 149
LCS distance to the health facility (proximity)
 Up to 100 m 8 (22.2) 11 (32.4) 2 (5.6) 8 (23.5) 3 (33.3) 32 (21.5) 8.643 0.071
 More than 100 m 28 (77.8) 23 (67.6) 34 (94.4) 26 (76.5) 6 (66.7) 117 (78.5)
Pricing of ACTs N = 20 N = 20 † N = 20 N = 27
 Affordable (GHC 1.5 or less)a 16 (80.0) 11 (55.0) † 14 (70.0) 17 (63.0) 58 (66.7) 3.092 0.378
 Not affordable  
(more than GHC 1.5)
4 (20.0) 9 (35.0) † 6 (30.0) 10 (37.0) 29 (33.3)
Availability of AMFm ACTs N = 20 (%) N = 21 (%) N = 22 (%) N = 20 (%) N = 8 (%) 91
 ACTs with green leaf logo 5 (25.0) 5 (23.8) 6 (27.3) 4 (20.0) 0 (0.0) 20 (22.0) 2.806 0.591
 Others 15 (75.0) 16 (76.2) 16 (72.7) 16 (80.0) 8 (100) 71 (78.0)
Table 3 Malaria management practices of  caregivers, 
N = 285
Description N (%)
Specific symptom that informed purchase of a drug
 Hot body 102 (37.8)
 Yellow urine 18 (6.7)
 Vomiting 39 (14.4)
 Body pains 10 (3.7)
 Diarrhoea 9 (3.3)
 Headache 32 (11.9)
 Convulsion 4 (1.5)
 Loss of appetite 45 (16.7)
 Other 11 (4.1)
Main reason you bought this particular drug
 Shopkeeper recommended 73 (67.6)
 Friend/neighbour/family 5 (4.6)
 It works better than other drugs 20 (18.5)
 Cost 3 (2.8)
 Was recommended by a health worker 2 (1.9)
 Other 5 (4.6)
Formulation of drug purchased
 Tablet 47 (43.5)
 Syrup 28 (25.9)
 Dispersible 27 (25.0)
 Other 6 (5.6)
How will you give (or take) the medicine
 Oral (tablet) 34 (37.8)
 Oral (dispersible) 43 (47.8)
 Injection 1 (1.1)
 Others 12 (13.3)
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  • “After few days the symptoms didn’t stop but had 
worsened”.
  • “Because after given the paracetamol syrup the tem-
perature did not go away”.
  • “Because I normally go there before the need for hos-
pital.”
  • “Best place to visit for immediate support or medical 
assistance.”
  • “Even the hospital approves of that shop and the 
price of the hospital and the shop is the same.”
  • “I decided to go to the drug shop because my child 
was crying each and every day and was not eating 
any food I gave him.”
  • “I decided to go to the drug store because the first 
time my child developed that same conditions, a 
friend of mine (a nurse) introduced me to the drug 
and it worked very well for me.”
  • “I think going to the drug shop is important because 
the same drugs would have been given if I had gone 
to the hospital or health centre.”
  • “I was using it as first aid so that if the symptoms do 
not go I will visit the hospital.”
  • “I went there because I have seen them to be quali-
fied people.”
  • “I was given the same treatment when I went to the 
hospital that is why I decided to go to the shop the 
second time.”
  • “That woman is very good and she gives good treat-
ment.”
Caregivers were thereafter questioned as to why or not 
they thought they were given a good treatment for their 
children’s illness. Some of the responses given were;
  • “After giving the drug I noticed the hotness and cold 
went away.”
  • “After the first dose, the child’s headache stopped.”
  • “Because it stopped the fever of the child.”
  • “Because my child’s rise in temperature went down, 
her urine came back to its normal colour”.
  • “Because the child has started playing and eating.”
  • “Because the fever and vomiting went away.”
  • “The child became well after the full course.”
  • “The fever subsided after the first dose.”
When asked about how they knew their children were 
well again, caregivers attributed various reasons. Most 
of the caregivers said they knew because their children 
started playing again, child’s temperature reduced, child 
was able to breastfeed and because their children stopped 
vomiting and crying. Most of the caregivers, when asked 
whether they will return to the drug shop, responded that 
they will return.
National level policy makers’ views on commodity supply 
chain management, availability and quality
The views of national level policy makers on the above 
subject, and their contribution to ensuring a smooth sup-
ply of quality-assured malaria prevention and treatment 
commodities are summarized below.
AMFm supply chain management
Policy makers at the national level are seen to contribute 
greatly to AMFm supply chain management in malaria 
control. This involves program design, implementation, 
supervision and coordination of procurement processes. 
Policy makers regulate activities of both the public and 
private healthcare levels in Ghana. Some of the responses 
given by policy makers in relation to their involvement in 
AMFm supply chain management are as follows;
“My roles include providing technical support in 
developing policies and guidance for malaria con-
trol. Help in resource mobilization, monitoring and 
supervision” (Policy Maker 1).
“We ensure that ACTs are in country, are available 
at all facilities, and are sold at the right prices by 
negotiating with all stakeholders. We also explore 
the right public and private channel for distribution 
of drugs” (Policy Maker 2).
“It is our role to ensure that effective preventive 
interventions and anti-malaria medicines are avail-
able and accessible to the entire population” (Policy 
Maker 3).
“There is a task team for coordinating all activities 
of the AMFm, marketing, training of health officials, 
ensuring drug safety and quality and liaising with 
all stakeholders to ensure effective functioning of the 
program” (Policy Maker 4).
Improving quality and availability of care in Ghana
Policy makers were of the view that quality and avail-
ability of care involves adhering to the right policies and 
guidance principles of the health service. Availability and 
proper coordination of resources contributes efficiently 
to the quality of care and this involves training of health-
care practitioners in ensuring proper diagnosis before 
treatment, sourcing or procuring malaria medications 
directly from WHO or WHO-accredited outlets were 
also considered relevant by policy makers.
“It is my view that there are good policies, protocols, 
and guidelines already in place for quality of health 
care in Ghana and all that is needed is ensuring 
compliance” (Policy Maker 1).
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“In improving quality of care, there should be bet-
ter commitment and effort from all those involved in 
malaria management” (Policy Maker 2).
“To ensure quality of drugs for health care, procure-
ments are only made from World Health Organiza-
tion’s (WHO) approved sources” (Policy Maker 3).
“In improving quality of care and treatment of 
malaria, there should be the availability and use 
of Rapid Diagnostic Test (RDT) in remote areas 
for testing of all cases before treatment, I think it is 
effective. It is better than presumptive diagnosis, its 
time saving and easy to use” (Policy Maker 4).
“Ensure households get prompt access to malaria 
treatment, home based care, partnering with agen-
cies and training of CHW. Ensuring quality ACTs 
available at affordable prices and link diagnosis to 
treatment of malaria” (Policy Maker 5).
Discussion
As an innovative global financing mechanism for the 
provision of QAACTs across the private as well as 
the public health sectors in high malaria endemic set-
tings, the AMFm programme sought to expand access 
to potent malaria management medications and ulti-
mately improve case management and possibly influence 
the rate of resistance development to currently recom-
mended anti-malarial. This study sought to evaluate the 
potential impact that AMFm subsidy and related policies 
have had on QAACT accessibility and childhood malaria 
management practices in hard-to-reach areas of Ghana 
where health infrastructure and systems are weak. The 
study evaluated the programme in Ghana, one of the 
eight AMFm implementing countries and was done after 
the official end of the programme to assess potential ben-
eficial impact beyond the policy implementation period. 
This study also provides a unique insight on the anti-
malarial market and extended the possible policy rami-
fications of the AMFm strategy by including viewpoints 
from key stakeholders such as health policy managers 
and national disease control officers.
The findings from the study indicate high ACT avail-
ability, adequate provider knowledge and reasonably 
low QAACT process in the study areas, all of which 
are a reflection of a high market share of ACT in these 
hard-to-reach areas of the country. The findings indicat-
ing high artesunate -amodiaquine (AA) and artemether-
lumefantrine (AL) availability reflect the relative longer 
existence of these respective ACT in Ghana to the 2005 
ACT policy implementation which recommended AA as 
first-line treatment for uncomplicated malaria and AL as 
an alternative for those who do not tolerate AA (Malaria 
Control Programme Policy 2005). The relatively low dihy-
droartemisinin-piperaquine availability reflects the fact 
that this ACT though among the recommended first-line 
treatments for uncomplicated malaria in Ghana, was only 
introduced later (in 2009) when the original policy was 
reviewed.
These findings of widespread AMFm QAACTS in 
hard-to-reach areas in Ghana, therefore, do not confirm 
expressed fears in certain quarters regarding the possi-
bility of market profiteering by middlemen in the ACT 
distribution chain. The findings also partially negate the 
notion of market forces in the private sector being nec-
essarily problematic in relation to ACT availability. How-
ever, the somewhat enduring presence of monotherapies, 
particularly that of amodiaquine is worrying and may 
be due to the particular emphasis that health education 
messages aimed at discouraging anti-malarial monother-
apies laid on artemisinin monotherapies per se. This mes-
saging strategy, while laudable and an important effort 
to protect these crucial anti-malarial may have inadvert-
ently deflected the focus from other important (availa-
bility-wise) anti-malarial, such as amodiaquine, which 
has been in use in Ghana for a long time. These con-
siderations are supported by the finding from previous 
studies indicating artesunate monotherapy as the second 
topmost selling anti-malarial in urban Nigeria [14]. The 
continuous presence of anti-malarial monotherapies in 
hard-to-reach-areas of the country, in spite of the fact 
that regulations discouraging manufacture, distribution, 
importation or sale of anti-malarial monotherapy are in 
operation in Ghana is a rallying call for strengthening 
applicable regulatory implementation procedures to the 
supply chain management and stricter enforcement of 
the applicable market authorization regulations regard-
ing these anti-malarials.
The data indicating adequate recognition of childhood 
malaria symptoms by LCS attendants also points towards 
appreciable familiarity with other relevant global child-
hood initiatives such as the integrated management of 
new-born and childhood illness (IMNCI) standards and 
requirements. While the encouraging findings indicat-
ing that majority of LCS attendants provided specific and 
adequate pre-dosing preparation instruction, or appro-
priate dosing and storage information to caregivers is 
likely due to satisfactory internalization of the widely-
circulated instructional and promotional messages that 
accompanied the AMFm green leaf logo implementa-
tion programme, the findings indicating that some LCS 
attendants in some of the study areas did not sell ACT 
to caregivers, or sold either incomplete courses of anti-
malarial medications or gave instructions inconsistent 
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with complete dosing is worrisome. These LCS attend-
ants were in the minority but the potential implications 
of selected expressions (e.g., “give two times in a day for 
two days and come for the third dose some other time”) 
on the possibility of perpetuating the resistance-promot-
ing sub-therapeutic anti-malarial drug concentrations 
should not be disregarded. Thus, education and training 
activities aimed at improving malaria management prac-
tices should be appropriately targeted and intensified. 
This also suggests that a more rigorous implementation 
of malaria management practice with specific informa-
tion on the dangers and implications of under-dosing or 
incomplete treatment of malaria should be undertaken at 
the national level, preferably through appropriate addi-
tions to the Standard Treatment Guidelines.
The relatively lower AMFm ACT prices confirm expec-
tations and findings from previous studies concluding 
that AMFm medications are less expensive than their 
counterparts [14], and is a reflection of the high market 
penetration of QAACT even in these hard-to-reach areas 
and thus of the impact of the AMFm policy. However, 
since the AMFm goal of increasing access has not suffi-
ciently extricated the concept of availability from afforda-
bility, both of which are viewed as critical to accessibility, 
the close overlap makes distinguishing between some of 
the associated variables problematic. While unafford-
ability is a major barrier to accessing ACT in countries 
where malaria is widespread [15, 16], the findings from 
this study that the national level price recommended for 
retailing AMFm QAACT at [1.50 Ghana cedis ($ 0.40) 
or less] was considered by majority of the participants as 
affordable. Thus, even in these hard-to-reach areas where 
the majority of the population could be described to be 
of low socio-economic status, QAACT provided through 
the AMFm programme were affordable [17], confirming 
the impact of the policy. However, not all retailers (with 
few exceptions) were selling at the recommended price, 
thus, raising affordability concerns for those without 
health insurance in these hard-to-reach areas. Overall, 
though, the findings generally confirm those from previ-
ous studies showing that AMFm ACT was less expensive 
than the non-AMFm counterparts [14].
From the point of view of some national health officials, 
the procurement process requirements of the AMFm 
programme requiring a global sourcing route resulted 
in regional health officials not able to obtain the entire 
QAACT requirements for the needs of their respec-
tive areas. This frequently raised the need to procure 
additional supplies of ACT from approved private sec-
tor suppliers. However, this raised availability as well as 
affordability concerns as it resulted at times in increased 
cost of the AMFm drugs.
The study findings indicating a preference by caregiv-
ers for LCS over health facilities for seeking treatment 
solutions to childhood malaria is consistent with findings 
from previous studies from Ghana [18, 19]. These find-
ings also corroborate findings from earlier studies from 
Ghana indicating that majority of treatments for child-
hood malaria occurs outside the public health system 
[20], and with findings from elsewhere concluding among 
others that, mothers are capable of treating childhood 
malaria at home [21]. The viewpoints expressed in one 
of the FGD to the effect that I was given the same treat-
ment when I went to the hospital that is why I decided to 
go to the shop the second time, is particularly interesting 
and merits further studies to explore the underlying rea-
soning, as well as potential implications of such asser-
tions. The importance of the other sentiments relating 
to affordability and cost of health care including those 
indicating a higher preference for the LCS rather than the 
health facility for childhood malaria symptoms, together 
with the FGD statement(s) to the effect that I did not 
have enough money at home as at the time the symptoms 
started so I decided to get First Aid at the drug store” or, 
“I do not have insurance so I went to the drug shop so that 
the cost would be less than the hospital further empha-
size the critical need for financial barrier removal. In 
this respect, interventions aimed at enhancing registra-
tion with the National Health Insurance Scheme as well 
as improving effective implementation of the NHIS are 
all important determinants in ensuring easier access to 
childhood malaria management options.
The expressed viewpoints by some respondents of not 
having enough money hence their decision to visit the 
LCS rather than a health facility is consistent with find-
ings from a previous study from Kenya [22], and with the 
general conclusions from other studies to the effect that 
the AMFm was indeed a good policy to increase access to 
QAACT for the poor [1, 23]. However, it is interesting to 
note that obvious logistic, systemic and perceived or real 
administrative barriers, including notions of overcrowd-
ing and long waiting hours at health centres were among 
some of the important factors that purportedly discour-
aged caregivers from seeking care at health facilities. 
While health facilities have closing hours, LCS are open 
at hours that are convenient to the community including 
weekends and holidays and may sometimes sell on credit 
basis to their customers [17]. These factors contribute to 
the provision of an obvious convenience advantage that is 
difficult to resist given the circumstances. Furthermore, 
the uneven distribution of health facilities in developing 
countries and the relative difficult health facility accessi-
bility plays an influential role in the use of formal health-
care [24, 25]. This is confirmed by the findings from a 
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study in Kenya indicating a reduction in the number of 
patients seeking care in formal health facilities as the 
distance from health facilities increased [24], and by 
the findings from studies in Burkina Faso and Tanzania 
showing that majority of the population obtains malaria 
medicines at licensed chemical shops [26–28], probably 
due to the same reason. The indirect cost of travelling 
long distance and long waiting time in health facilities are 
all factors that influence decision to visit LCS, therefore, 
underscoring the important role of removing physical 
and financial barriers to improve access to health care in 
countries such as Ghana.
Overall the findings from the study indicate the AMFm 
programme to be functional in Ghana and showing posi-
tive impact of the programme following its implementa-
tion in Ghana. Specifically, the AMFm policy contributed 
to widespread awareness and availability of ACT medica-
tions in hard-to-reach areas of the country. The findings 
also indicate that the AMFm policy most likely enhanced 
affordability of QAACT in rural areas of Ghana. The 
important role of primary caregivers and LCS in child-
hood malaria management was also validated.
It is worthy of note, however, that some of the findings 
presented be interpreted with caution. For instance, the 
actions of the sample of 89 LCS attendants from the five 
study districts of the four regions of Ghana may not be 
representative of all LCS in Ghana. Therefore, the LCS-
related information provided may not be generalized 
beyond the study sites.
Conclusions
Overall the AMFm programme was very functional and 
producing results in Ghana at the time of this study. 
ACT drugs were the drugs most commonly available, 
prescribed and sold in health facilities and in LCS shops. 
There was a widespread awareness of ACT drugs and the 
AMFm Green Leaf logo. It appears from these data that 
ACT was made affordable for most people seeking treat-
ment from health facilities and LCS shops in rural areas. 
Caregivers and LCS were seen to play key roles in the 
health of the community especially with children under 
5 years of age.
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